drugset / Trial / NCT03349255
Clinical Study of ET1402L1-CAR T Cells in AFP Expressing Hepatocellular Carcinoma
Phase 1
Terminated
3 enrolled
Aeon Therapeutics (Shanghai) Co., Ltd.
Eureka Therapeutics Inc. · collabRenmin Hospital of Wuhan University · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
Clinical study to evaluate safety and pharmacokinetics (primary objectives) and efficacy (secondary objective) of ET1402L1-CART-cells in patients with AFP+ HCC
Timeline
- Start
- 2017-10-06
- Primary completion
- 2019-01-10
- Completion
- 2019-01-10
Outcome
Outcome not reported
Stopped: “Will study new T-cell construct for the same indication”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ET1402L1-CART | Unknown | — | Intravenous |